Global Investment For Therapeutics to End Duchenne (GIFTED)recebe propostas para financiamento de projetos de pesquisa na área distrofia muscular.
The Global Investment For Therapeutics to End Duchenne (GIFTED) is a fund that invests in three types of projects:
- Better: this funding program is designed to put better drug candidates into clinical testing and to decrease the failure rates for new Duchenne drug candidates;
- Faster: in addition to putting better drug candidates into clinical testing and reducing the failure rate, the ability to test drugs quickly and efficiently is another way GIFTED can provide value and leverage;
- Now: while there is a pressing need to develop new therapies for Duchenne, we also know enough about the pathways affected in the disease to identify drugs that have already been approved for other diseases that affect those same pathways. Those drugs can be tested now in human clinical studies with much less expense than new drugs.
The corporate funding program Drug Development Corporate Grant is part of PPMD's GIFTED initiative and is focused on the development of new drugs for Duchenne and Becker muscular dystrophy (the "dystrophinopathies"). The ideal project will yield data that will help a company raise funds from other investors to move the candidate forward to the next stage of clinical development.
Data Limite Rolling date.
Elegibilidade Any biotechnology company or pharmaceutical company developing a therapy that can be tested in and applied to Duchenne muscular dystrophy. Applicants do not have to be US-based. Projects that require PPMD funding to progress will be prioritized over well-funded projects
Available funding categories:
Bridge Funds: US$50 - US$300K;
Pre-IND projects: US$500K - US$1M;
Phase I, II studies: US$1M - US$1.5M.
Fonte As informações descritas acima foram obtidas na homepage e por contato direto com a Financiadora.
Para maiores informações, clique aqui